FibroBiologics Secures Australian Patent Acceptance for Cannabidiol-Fibroblast Combination in Disc Degeneration

FibroBiologics has added a jurisdiction to its intellectual property estate that clinical and regulatory teams developing cell therapy programs in the Asia-Pacific region will need to track. IP Australia has accepted Patent Application No. 2020368344, covering methods of treating degenerative disc disease through the co-administration of cannabidiol and fibroblast-based cell therapy — a combination the Houston-based company positions as both regenerative and cytoprotective.

The accepted application is broader than a single delivery route. Claims cover systemic, transdermal, and intradiscal cannabidiol administration, and extend to fibroblasts differentiated into notochord cells or chondrocytes intended to replenish the nucleus pulposus. The application also claims cannabidiol's role in augmenting fibroblast production of growth factors, specifically IGF-1 and EGF-1, which are implicated in extracellular matrix remodeling and disc cell survival.

For development teams working on cell therapy manufacturing, the differentiation pathways cited — fibroblasts to notochord cells or chondrocytes — carry process development implications. Characterization of these intermediates, demonstration of phenotypic stability, and potency assay design will be central to any regulatory submission in markets where this patent now holds accepted status. Australian Therapeutic Goods Administration requirements for biologics and cell therapies operate under a framework that expects robust comparability data when manufacturing processes evolve.

FibroBiologics reports a portfolio of more than 270 issued and pending patents spanning wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, and oncology. The disc degeneration pathway is one of the company's named core clinical programs, and this acceptance extends its IP coverage into a market where cell therapy regulatory pathways are maturing alongside clinical interest.

The measurable next checkpoint for this program is translation of the accepted patent claims into a clinical protocol that satisfies both the biological rationale described in the application and the manufacturing controls regulators will require for a combination approach involving a cannabidiol adjuvant and a live-cell therapeutic.

Source: FibroBiologics, Inc. press release via PR Newswire, 20 August 2026.